HbA1c (glycated hemoglobin) reflects your average blood glucose over the past 90 days, capturing glycemic control more reliably than a single fasting glucose measurement. It is the gold standard for detecting prediabetes and diabetes, and a powerful predictor of cardiovascular and microvascular complications across the lifespan.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
You should consider HbA1c testing if you have a family history of diabetes, metabolic concerns (weight gain, fatigue, poor energy recovery), or cardiovascular risk factors. Unlike a single fasting glucose measurement, HbA1c reveals your glucose control pattern over three months — the time it takes for red blood cells to turn over — giving your clinician a far more complete picture of metabolic health.
Even if you feel well, HbA1c testing is proactive. Prediabetes often develops silently; catching elevated glycated hemoglobin early opens a window for dietary, training, and lifestyle intervention before diabetes develops. For those with family history or metabolic syndrome markers (elevated triglycerides, low HDL, increased waist circumference), HbA1c is essential baseline data.
Measures 90-day glucose trajectory. HbA1c captures your average blood glucose over three months, filtering out the noise of daily fluctuations and single-point measurements.
Detects prediabetes and diabetes early. Identifies dysglycemia before symptoms appear, enabling preventive intervention when metabolic correction is most achievable.
Predicts cardiovascular and microvascular risk. Elevated HbA1c is independently associated with increased risk of myocardial infarction, stroke, and diabetic complications (neuropathy, nephropathy, retinopathy).
Guides therapeutic targets. HbA1c provides the quantitative benchmark for assessing efficacy of lifestyle or pharmacological intervention in real time.
Contextualizes related markers. HbA1c interpretation deepens when paired with fasting glucose, fasting insulin, and HOMA-IR, revealing both absolute glycemic load and insulin resistance patterns.
Tracks metabolic aging. Rising HbA1c despite stable weight or stable fasting glucose signals declining pancreatic insulin secretion or increasing insulin resistance — early warning of metabolic deterioration.
The mechanism: non-enzymatic glycation of hemoglobin. When glucose circulates at elevated levels, it binds irreversibly to the NH2 group of the beta-globin chain in hemoglobin through a process called non-enzymatic glycation. This binding is proportional to the time-weighted average of glucose exposure — the higher and more sustained the glucose levels, the more hemoglobin molecules become glycated. Red blood cells live roughly 120 days; HbA1c therefore reflects the mean glucose over the preceding 90 days.
Why this matters for longevity. Persistent hyperglycemia drives endothelial dysfunction through several converging mechanisms: glycation of vascular proteins impairs nitric oxide signaling; reactive oxygen species from the polyol pathway and mitochondrial electron leakage damage endothelial cells; and chronic low-grade inflammation accelerates atherosclerotic plaque formation. HbA1c predicts cumulative vascular injury better than fasting glucose alone because it captures the full 24-hour glycemic exposure, including postprandial spikes that single glucose measurements miss.
Swedish laboratory reporting standard. Swedish clinical laboratories report HbA1c in IFCC units (mmol/mol, moles of glucose per mole of hemoglobin) as the primary measurement, with NGSP percentage (%) as a secondary reference for international comparison. Understanding both units is essential: 48 mmol/mol (6.5%) is the diagnostic threshold for diabetes globally; 36 mmol/mol (5.4%) represents optimal metabolic health and longevity targeting.
Silent progression to diabetes. Prediabetes develops without symptoms; HbA1c detects dysglycemia at the reversible stage. Once HbA1c exceeds 42 mmol/mol (6.0%), the risk of progression to diabetes accelerates, but lifestyle intervention at this threshold can halt or reverse the trajectory.
Cardiovascular risk independent of diagnosis. Even in the prediabetic range (42–47 mmol/mol), HbA1c elevation is associated with increased atherosclerotic risk, endothelial dysfunction, and arterial stiffness — years before diabetes is formally diagnosed.
Insulin resistance clustering. Elevated HbA1c often clusters with other metabolic dysfunction markers: elevated fasting insulin, high HOMA-IR, elevated triglycerides, and low HDL. This constellation amplifies vascular risk far beyond HbA1c alone.
Guides preventive intervention timing. HbA1c tiers map onto intervention urgency: optimal (<36 mmol/mol) requires maintenance; prediabetic (42–47 mmol/mol) requires structured dietary and training changes; diabetic (≥48 mmol/mol) requires medical evaluation. Testing reveals where you stand and what intervention category applies.
Standard Swedish reference (vårdcentralen): <42 mmol/mol (<6.0%). This is the non-diabetic range; HbA1c below this threshold carries standard baseline metabolic risk.
Loovi optimal (longevity): <36 mmol/mol (<5.4%). This represents proactive glucose control and is associated with minimal vascular aging and optimal longevity outcomes in observational and interventional studies.
Prediabetic range (ESC/EASD clinical threshold): 42–47 mmol/mol (6.0–6.4%). This tier signals dysglycemia and substantially elevated risk of progression to diabetes within 5–10 years; intensive lifestyle intervention is warranted.
Diabetic range (clinical diagnosis threshold): ≥48 mmol/mol (≥6.5%). Diagnostic of diabetes mellitus per WHO, ESC, and EASD guidelines; medical evaluation and treatment initiation are indicated.
The delta between 36 and 42 mmol/mol (5.4–6.0%) is not trivial: every 1 mmol/mol rise in HbA1c above 36 progressively increases cardiovascular event risk. Most Swedish adults achieve <42, but longevity-focused testing aims for <36, especially in those with family history or established cardiovascular risk factors.
Low HbA1c (<36 mmol/mol / <5.4%). Reflects sustained glycemic control and minimal vascular stress from hyperglycemia. In the absence of other metabolic dysfunction (low triglycerides, normal fasting insulin, normal HOMA-IR), this pattern indicates robust glucose handling and is associated with lower cardiovascular event rates and slower vascular aging.
Optimal HbA1c (36–42 mmol/mol / 5.4–6.0%). Represents the standard non-diabetic range and reflects adequate glucose control for most individuals. However, HbA1c in this zone can mask heterogeneity: someone with stable fasting glucose and low postprandial spikes may cluster at the lower end, while someone with postprandial hyperglycemia may sit at the upper end with similar overall HbA1c. Pairing HbA1c with fasting glucose and the glucose response to oral challenge (via continuous glucose monitoring or postprandial testing) reveals these patterns.
Elevated HbA1c (42–47 mmol/mol / 6.0–6.4%, prediabetic range). Indicates dysglycemia and substantially elevated risk of progression to diabetes. This range often reflects insulin resistance, impaired beta-cell insulin secretion, or both. Biochemically, the endothelium is already experiencing glycation-driven dysfunction; inflammation markers (hs-CRP) and triglycerides often climb at this stage. This is the pivotal window: intensive lifestyle intervention (structured carbohydrate distribution, resistance training, sleep and stress optimization) can halt or reverse progression.
High HbA1c (≥48 mmol/mol / ≥6.5%, diabetic range). Meets diagnostic criteria for diabetes mellitus. Indicates sustained hyperglycemia and requires medical evaluation to establish type, severity, complication screening, and initiation of pharmacological therapy if indicated. HbA1c at this level predicts microvascular complications (nephropathy, neuropathy, retinopathy) within 10–15 years without intervention.
Factors that influence HbA1c. HbA1c can be skewed by conditions that alter red blood cell turnover or hemoglobin structure: anemia (including iron deficiency and B12 deficiency) artificially raises HbA1c; hemoglobinopathies (HbS, HbC, thalassemia trait) interfere with measurement; recent blood loss or transfusion introduces younger RBCs with lower glycation; pregnancy lowers HbA1c due to shortened RBC lifespan and hemodilution; chronic kidney disease and chronic liver disease impair glucose metabolism and can skew results; intense endurance training or high-altitude exposure can transiently lower HbA1c. When these confounders are present, fructosamine (measuring glycation of serum albumin over 2–3 weeks) offers better short-term glucose assessment than HbA1c.
Insulin resistance and metabolic syndrome. The predominant driver in non-diabetic populations. Resistance in muscle and adipose tissue forces the pancreas to oversecrete insulin to maintain glucose homeostasis; over time, beta-cell exhaustion ensues and fasting and postprandial glucose rise. HbA1c climbs as glucose levels exceed the renal reabsorption threshold and glycemic control deteriorates.
Beta-cell dysfunction and insufficient insulin secretion. As prediabetes progresses, pancreatic beta cells fail to compensate for rising insulin resistance, resulting in inadequate glucose-stimulated insulin secretion. HbA1c rises despite normal or near-normal fasting glucose because postprandial glucose excursions become pronounced.
Genetic predisposition and family history. Familial clustering of type 2 diabetes reflects polygenic inheritance of insulin secretion capacity and tissue insulin sensitivity. Individuals with first-degree relatives with diabetes have substantially elevated lifetime risk; HbA1c trends early in these lineages warrant closer surveillance.
Aging and declining beta-cell function. Pancreatic beta-cell mass and insulin secretion capacity both decline with age, particularly after age 40. Coupled with age-related increases in insulin resistance, HbA1c tends to rise incrementally across the lifespan in most populations — a pattern Loovi testing captures and contextualizes against individual baselines.
Inflammation and dietary pattern. Chronic low-grade inflammation (reflected in elevated hs-CRP) associates with insulin resistance; diets high in refined carbohydrates and processed foods drive postprandial hyperglycemia spikes and accelerate beta-cell dysfunction. The reverse—anti-inflammatory dietary patterns rich in intact carbohydrates, fiber, and polyphenols—associates with improved insulin sensitivity and lower HbA1c.
Nutrition — carbohydrate quality and glycemic distribution. Carbohydrate quality matters more than total carbohydrate quantity for glycemic control. Intact whole grains, legumes, vegetables, and fruits with high fiber density produce lower postprandial glucose spikes than refined grains and simple sugars. Distributing carbohydrate intake across the day (rather than front-loading a large breakfast or dinner) blunts peak glucose excursions. Added sugars and ultra-processed foods drive rapid glycemic swings and worsen insulin resistance.
Resistance training and physical activity. Muscle is a primary glucose sink; resistance training increases GLUT4 glucose transporter expression in myocytes and enhances insulin-stimulated glucose uptake, directly lowering fasting glucose and improving HbA1c. Regular aerobic activity improves mitochondrial insulin sensitivity and reduces hepatic gluconeogenesis. The combination of resistance and aerobic training (3–5 sessions per week) produces more robust HbA1c reduction than either alone.
Sleep, stress, and circadian alignment. Sleep deprivation and chronic psychological stress elevate cortisol and suppress insulin secretion, worsening hyperglycemia and raising HbA1c over time. Consistent sleep duration (≥7 hours nightly), consistent sleep–wake timing, and stress-management practices (meditation, time in nature, social connection) restore insulin sensitivity and support HbA1c control.
Pharmacological intervention (when indicated). Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity; GLP-1 receptor agonists (semaglutide, tirzepatide) enhance beta-cell insulin secretion and slow gastric emptying, reducing postprandial glucose spikes; SGLT2 inhibitors promote renal glucose excretion. The choice and combination depend on individual baseline HbA1c, insulin resistance severity, and comorbid conditions—a decision reserved for clinician consultation.
Optimization depends on the individual's baseline HbA1c, degree of insulin resistance (assessed via HOMA-IR and fasting insulin alongside HbA1c), and family history. A Loovi longevity doctor maps these factors in consultation and designs a targeted intervention plan.
HbA1c is a powerful marker, but it tells an incomplete story on its own. A normal HbA1c can mask postprandial hyperglycemia (high glucose spikes after eating) if most of the day's glucose excursions occur in the hours after meals — continuous glucose monitoring or oral glucose tolerance testing reveals this pattern. Conversely, HbA1c can be elevated in the prediabetic range while fasting glucose remains completely normal, signaling that insulin resistance is primarily postprandial, not fasting.
HbA1c's predictive power multiplies when paired with related biomarkers. Fasting glucose and fasting insulin reveal baseline metabolic state; HOMA-IR quantifies insulin resistance severity; triglycerides and apolipoprotein B reflect hepatic lipogenesis and metabolic load; and hs-CRP captures systemic inflammation, which independently accelerates atherosclerosis in the setting of dysglycemia. Together, these markers reveal whether glucose dyscontrol is the primary driver of vascular risk, or whether it clusters with lipid dysfunction and inflammation to create a more aggressive metabolic phenotype.
Loovi's 120+ biomarker annual tracking captures this full metabolic picture alongside physical performance metrics (VO2 max, strength, mobility). A longevity doctor then contextualizes your HbA1c within your complete metabolic, inflammatory, and cardiovascular risk profile — and designs an intervention strategy tailored to your individual genetics, lifestyle, and biomarker clustering.
Fasting glucose is a snapshot of your blood sugar after 8–12 hours without eating — it reveals your baseline hepatic glucose output and basal insulin secretion. HbA1c is a three-month time-weighted average reflecting all 24-hour glucose exposures, including postprandial (after-meal) spikes. Someone can have normal fasting glucose (<5.6 mmol/L) but elevated HbA1c (>42 mmol/mol) if they have pronounced postprandial hyperglycemia; conversely, someone with slightly elevated fasting glucose but excellent glucose control the rest of the day may have lower HbA1c. Testing both reveals whether dysglycemia is primarily fasting-driven or postprandial-driven.
Yes, particularly if your glucose monitor or spot measurements capture only your fasting state or the non-peak hours. Many people experience pronounced glucose spikes 30–90 minutes after meals without realizing it; these daily spikes accumulate into elevated HbA1c over weeks. Continuous glucose monitoring reveals the full glycemic profile and is far more informative than periodic spot checks.
Insulin resistance is the upstream driver of HbA1c elevation in most people. When muscle and adipose tissue resist insulin, the pancreas compensates by secreting more insulin to maintain glucose homeostasis — initially maintaining normal fasting glucose, but at the cost of chronically elevated insulin and exaggerated postprandial spikes. As beta-cell exhaustion develops over years, fasting and postprandial glucose both rise, and HbA1c climbs. Measuring fasting insulin and HOMA-IR alongside HbA1c reveals how much insulin resistance is driving your glucose dyscontrol.
Yes, significantly. Anemia (low red blood cell count or hemoglobin) shortens RBC lifespan and introduces younger cells with less time to accumulate glycation, artificially lowering HbA1c. Conversely, conditions that extend RBC lifespan (such as certain anemias or polycythemia) can elevate HbA1c. Hemoglobinopathies (HbS, HbC, thalassemia trait) interfere with HbA1c measurement and render the result unreliable. If you have anemia, blood disorders, or recent transfusion, discuss HbA1c interpretation with your clinician or use fructosamine instead.
Yes. Pregnancy lowers HbA1c due to hemodilution and accelerated red blood cell turnover; HbA1c can drop 0.5–1.0 percentage point below your non-pregnant baseline. This means standard HbA1c thresholds for diabetes diagnosis do not apply during pregnancy; gestational diabetes is diagnosed via fasting glucose and oral glucose tolerance test instead. After delivery, HbA1c returns to your baseline within weeks.
HbA1c changes lag behind actual glucose control improvements because it reflects the prior 90-day glucose average. If you adopt intensive lifestyle intervention (carbohydrate optimization, resistance training, sleep and stress management), you will see improvements in fasting glucose within days to weeks, but HbA1c will take 8–12 weeks to meaningfully decline — you're waiting for your RBC population to fully turn over and accumulate new glycation levels reflecting the improved glucose environment. Substantial HbA1c reductions (1–2 mmol/mol or more) typically emerge after 12–16 weeks of consistent intervention.
Yes. Prediabetes and early type 2 diabetes are asymptomatic; you will not feel hyperglycemia until complications develop. Baseline HbA1c testing in your 30s or 40s provides essential reference data. If your HbA1c is optimal (<36 mmol/mol), continue annual testing to ensure it remains stable. If it begins to drift upward, early detection enables preventive intervention before the prediabetic range is reached.
HbA1c predicts cardiovascular events independently of diabetes diagnosis. Elevated HbA1c (even in the prediabetic range, 42–47 mmol/mol) associates with endothelial dysfunction, arterial stiffness, and accelerated atherosclerosis. When HbA1c clusters with high apolipoprotein B, elevated triglycerides, and elevated hs-CRP, vascular risk amplifies dramatically — this is why contextualizing HbA1c within your full lipid and inflammatory profile is essential.
Yes. Corticosteroids (prednisone, dexamethasone) worsen hyperglycemia by suppressing insulin secretion and increasing hepatic gluconeogenesis, raising HbA1c over weeks; antipsychotics cause metabolic syndrome and insulin resistance; beta-blockers may slightly impair insulin secretion; thiazide diuretics worsen glucose control at higher doses. If you are on long-term medications, discuss their potential metabolic effects with your clinician; HbA1c trends under medication often reflect the underlying drug-induced metabolic shift.
HbA1c is a powerful predictor of lifespan and healthspan. Cohort studies and Mendelian randomization evidence show that every 1 mmol/mol increase in HbA1c above 36 progressively raises all-cause mortality risk through cardiovascular, renal, and metabolic mechanisms. Maintaining HbA1c <36 mmol/mol (<5.4%) without overtreatment is associated with optimal metabolic health, minimal vascular aging, and extended healthspan in aging studies. This is why Loovi targets this range as a longevity benchmark.
